OSE Immunotherapeutics receives the Euronext Tech 40 Label

24 May 2018

Nantes, France, April 23 2018, OSE Immunotherapeutics, a member of Atlanpole Biotherapies, has received the Euronext Tech 40 Label and is thus admitted to the “Tech 40” index.

Wanting to give more prominence to outstanding listed Tech companies, every year Euronext grants its Tech 40 label to 40 European and outstanding Tech companies listed on the various Euronext markets (Paris, Amsterdam, Brussels and Lisbon)
The companies receiving this label were chosen by a committee of independent European experts, based on their business, financial and stock market performance.
Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, said: “We are very pleased that OSE Immunotherapeutics has been chosen to receive the Euronext Tech 40 Label. This reaffirms the innovative approach of our immunotherapies and should enable us to further increase our visibility among European and international investors.

Press Release